A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

A gene called high mobility group A1 (HMGA1) may be the key that opens the door to the development of colon cancer, according ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full ...

Sequenom's MassARRAY ® system enables sensitive and rapid somatic mutation profiling in solid tumors or cell lines. Our validation studies revealed mutations in most of the oncogenes analyzed ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says. Taking 160 milligrams of aspirin a day cuts the risk of cancer ...

Genetic and environmental disruptions to circadian clocks accelerate the progression of colorectal cancer in organoids and mice, University of California, Irvine, researchers report in an August 10 ...

Pfizer’s metastatic colorectal cancer (mCRC ... the combination in mCRC patients living with a BRAF V600E mutation who are treatment-naive. The top-line data also saw statistically significant ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...